Regeneron Pharmaceuticals, Inc.
HIGH CONCENTRATION ANTI-C5 FORMULATIONS

Last updated:

Abstract:

The present disclosure includes high concentration, low viscosity pharmaceutical formulations that include an anti-C5 antibody or antigen-binding fragment thereof and arginine. Such formulations may be provided in association with an RNAi molecule such as cemdisiran. Methods of treating C5-associated diseases such as PNH and aHUS are also provided.

Status:
Application
Type:

Utility

Filling date:

14 Aug 2020

Issue date:

18 Feb 2021